Osaka Medical Center for Cancer and Cardiovascular Diseases Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3

Organization Overview

First Clinical Trial
1996
NCT00152178
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2013

Timeline

NOW
  • Now

Alternative names

Osaka Medical Center for Cancer and CVD

Active Ingredients

Drugs in Phase 3 Trials (5)

tamoxifen (nolvadex) (1 trial)

tegafur (2 trials)

temsirolimus (torisel) (1 trial)

uracil (1 trial)

vinorelbine (navelbine) (1 trial)

Drugs in Phase 2 Trials (4)

gemcitabine (gemzar) (2 trials)

gimeracil (1 trial)

oteracil (1 trial)

s-1 (1 trial)

Drugs in Phase 1 Trials (1)

paclitaxel (taxol) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 3)

Pancreatic Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 10